Lead Product(s) : TX01
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Theranexus and Exeltis License Tx01 for Two Rare Neurological Disorders
Details : Under the licensing agreement, Exeltis will acquire exclusive rights to market and distribute Theranexus' proprietary product TX01 for treating Gaucher & Niemann-Pick Disease Type C.
Product Name : TX01
Product Type : Undisclosed
Upfront Cash : $2.1 million
December 17, 2024
Lead Product(s) : TX01
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Grants Orphan Drug Designation for Vivet's Gene Therapy for CTX
Details : VTX-806, an Adeno-associated viral (AAV) vector encoding human CYP27A1 is being investigating for the treatment of Cerebrotendinous Xanthomatosis (CTX).
Product Name : VTX-806
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : French Government
Deal Size : $5.2 million
Deal Type : Funding
Vivet Receives EUR 4.9 Million for Gene Therapy Development
Details : Vivet will use funds to develop VTX-806, aiming to halt or reverse disease progression in cerebrotendinous xanthomatosis patients.
Product Name : VTX-806
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : French Government
Deal Size : $5.2 million
Deal Type : Funding
Lead Product(s) : SPVN20
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Tenpoint Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics
Details : Through the divestment, Tenpoint has acquired SparingVision's ex vivo GIRK technology. SparingVision will remain focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate.
Product Name : SPVN20
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 07, 2023
Lead Product(s) : SPVN20
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Tenpoint Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pre-clinical data presented at ESGCT further demonstrate our ability to leverage TALEN® gene editing technology to potentially address genetic diseases, namely, sickle cell disease and lysosomal storage diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FXS01
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Details : The publication of a peer-reviewed article for FXS01 in EMBO Molecular Medicine showing that adeno-associated viral (AAV) vector-delivered diacylglycerol kinase (DGKk) achieves long-term rescue of fragile X syndrome (FXS) in a mouse model of disease.
Product Name : FXS01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : FXS01
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the progr...
Product Name : VTX-803
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 04, 2021
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : FXS01
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Lysogene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus
Details : Lysogene will be responsible for the preclinical and clinical development, manufacturing, regulatory activities, and commercialization of the drug candidate, globally. which includes FXS01, a gene therapy candidate for the treatment of Fragile X syndrome...
Product Name : FXS01
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 06, 2021
Lead Product(s) : FXS01
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Lysogene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data presentation based on a preclinical development of a TALEN® based genome editing in T-cells for the treatment of two product candidates targeting primary immunodeficiencies: RAG1 for Severe Combined Immunodeficiency (SCID) and STAT3 for Hyper IgE s...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATA-100
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First approval of ATA-100, was received from UK MHRA its gene therapy for the treatment of the fukutin-related protein limb-girdle muscular dystrophy Type 2I/R9.
Product Name : ATA-100
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 12, 2021
Lead Product(s) : ATA-100
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable